{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T05:15:20Z","timestamp":1782882920781,"version":"3.54.5"},"reference-count":48,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sickle cell disease (SCD) remains the most common monogenic disorder worldwide, yet more than a century after its formal discovery, our treatment options and approach to care remain underdeveloped. Despite scientific progress, care for SCD continues to lag behind other chronic conditions, in part due to a lack of consensus on straightforward medical decision-making\u2014driven by a persistent paucity of data and compounded by historical neglect, systemic inequities, and clinical heterogeneity. To truly serve this vulnerable population, we must move toward a more comprehensive, personalized approach to adult care\u2014one that mirrors the individualized pain management plans routinely used in acute care settings. While much of the foundational work in SCD has been in pediatrics, this manuscript focuses on the adult population, where the burden of disease increases and access to specialized care declines. We emphasize the importance of considering genotype, hematologic profile, comorbid conditions, psychosocial context, and health literacy when developing treatment plans in shared decision-making with our patients. Ultimately, we hope this manuscript provides practical insights to help clinicians answer the daily complex questions surrounding sickle cell care: whom to treat and which interventions offer the most meaningful benefit for that particular patient.<\/jats:p>","DOI":"10.1182\/hematology.2025000753","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:10:02Z","timestamp":1764943802000},"page":"585-591","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["The right patient, the right treatment: tailoring sickle cell disease care"],"prefix":"10.1182","volume":"2025","author":[{"given":"Sheinei","family":"Alan","sequence":"first","affiliation":[{"name":"1 Inova Adult Sickle Cell Program, Inova Schar Cancer Institute, UVA School of Medicine, Fairfax, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payal","family":"Desai","sequence":"additional","affiliation":[{"name":"2 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"4","key":"2025120616350009700_hem2025000753C1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/ajh.26063","article-title":"Impact of sickle cell disease on patients' daily lives, symptoms reported, and disease management strategies: results from the international Sickle Cell World Assessment Survey (SWAY)","volume":"96","author":"Osunkwo","year":"2021","journal-title":"Am J Hematol"},{"issue":"11","key":"2025120616350009700_hem2025000753C2","doi-asserted-by":"crossref","DOI":"10.3390\/cells13110934","article-title":"End organ affection in sickle cell disease","volume":"29","author":"Bathla","year":"2024","journal-title":"Cells"},{"issue":"3","key":"2025120616350009700_hem2025000753C3","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1182\/blood-2005-10-009506","article-title":"Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results","volume":"108","author":"Lee","year":"2006","journal-title":"Blood"},{"issue":"12","key":"2025120616350009700_hem2025000753C4","first-page":"1254","article-title":"Periodic transfusions for sickle cell anemia and CNS infarction","volume":"133","author":"Sarnaik","year":"1979","journal-title":"Am J Dis Child"},{"issue":"17","key":"2025120616350009700_hem2025000753C5","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1182\/blood-2011-11-392340","article-title":"Stroke with transfusions changing to hydroxyurea (SWiTCH)","volume":"119","author":"Ware","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2025120616350009700_hem2025000753C6","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1182\/bloodadvances.2019001142","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults","volume":"4","author":"DeBaun","year":"2020","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2025120616350009700_hem2025000753C7","first-page":"4800","article-title":"Red cell exchange: a concise review of indications and management","volume":"130","author":"Biller","year":"2017","journal-title":"Blood"},{"key":"2025120616350009700_hem2025000753C8","unstructured":"Sickle Cell Disease and Cardiovascular Risk\u2014Red Cell Exchange Trial (SCD-CARRE). ClinicalTrials.gov identifier: NCT04084080. Updated 24April2025."},{"issue":"6","key":"2025120616350009700_hem2025000753C9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/MOH.0000000000000837","article-title":"Prophylactic red cell transfusions for sickle cell disease pregnancy: increased use of therapy could transform outcomes","volume":"31","author":"Alan","year":"2024","journal-title":"Curr Opin Hematol"},{"issue":"16","key":"2025120616350009700_hem2025000753C10","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1182\/bloodadvances.2024012923","article-title":"Prophylactic exchange transfusion in sickle cell disease pregnancy: a TAPS2 feasibility randomized controlled trial","volume":"8","author":"Oteng-Ntim","year":"2024","journal-title":"Blood Adv"},{"key":"2025120616350009700_hem2025000753C11","unstructured":"Prophylactic Transfusion in Pregnant Women With Sickle Cell Disease. ClinicalTrials.gov. Identifier: NCT06979492. Posted 13May2025."},{"issue":"8","key":"2025120616350009700_hem2025000753C12","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/trf.17924","article-title":"Chronic automated red cell exchange therapy for sickle cell disease","volume":"64","author":"Zakieh","year":"2024","journal-title":"Transfusion"},{"issue":"1","key":"2025120616350009700_hem2025000753C13","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/hematology.2023000498","article-title":"Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease","volume":"2023","author":"Kelly","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"2025120616350009700_hem2025000753C14","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/jca.22078","article-title":"Hemoglobin S target of &lt;50% as compared to 30% in chronic red cell exchange for secondary stroke prevention in sickle cell disease","volume":"38","author":"Choi","year":"2023","journal-title":"J Clin Apher"},{"issue":"11","key":"2025120616350009700_hem2025000753C15","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1517\/14740338.2015.1088827","article-title":"Hydroxyurea therapy for sickle cell anemia","volume":"14","author":"McGann","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"20","key":"2025120616350009700_hem2025000753C16","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N Engl J Med"},{"issue":"13","key":"2025120616350009700_hem2025000753C17","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/jama.289.13.1645","article-title":"Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment","volume":"289","author":"Steinberg","year":"2003","journal-title":"JAMA"},{"issue":"6","key":"2025120616350009700_hem2025000753C18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ajh.21699","article-title":"The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up","volume":"85","author":"Steinberg","year":"2010","journal-title":"Am J Hematol"},{"key":"2025120616350009700_hem2025000753C19","volume-title":"Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease: A Pocket Guide for the Clinician","author":"American Society of Hematology","year":"2014"},{"issue":"12","key":"2025120616350009700_hem2025000753C20","first-page":"1767","article-title":"Hydroxyurea at escalated dose versus fixed low-dose for sickle cell disease: a systematic review and meta-analysis","volume":"98","author":"Ogu","year":"2023","journal-title":"Am J Hematol"},{"key":"2025120616350009700_hem2025000753C21","volume-title":"ASH Clinical Practice Guidelines on Dosing and Monitoring of Hydroxyurea for Sickle Cell Disease","author":"American Society of Hematology","year":"2024"},{"issue":"1","key":"2025120616350009700_hem2025000753C22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1186\/s13063-023-07649-7","article-title":"Prospective identification of variables as outcomes for treatment (PIVOT): study protocol for a randomised, placebo-controlled trial of hydroxyurea for Ghanaian children and adults with haemoglobin SC disease","volume":"24","author":"Smart","year":"2023","journal-title":"Trials"},{"issue":"19","key":"2025120616350009700_hem2025000753C23","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/bloodadvances.2023011536","article-title":"Impact of hydroxyurea on follicle density in patients with sickle cell disease: a cross-sectional study of ovarian tissue","volume":"8","author":"Morrison","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"2025120616350009700_hem2025000753C24","doi-asserted-by":"crossref","first-page":"e0304241","DOI":"10.1371\/journal.pone.0304241","article-title":"Effects of hydroxyurea on fertility in male and female sickle cell disease patients. A systemic review and meta-analysis","volume":"19","author":"Sewaralthahab","year":"2024","journal-title":"PLoS One"},{"issue":"8","key":"2025120616350009700_hem2025000753C25","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/17474086.2024.2372320","article-title":"Sickle cell disease and infertility risks: implications for counseling and care of affected girls and women","volume":"17","author":"Pecker","year":"2024","journal-title":"Expert Rev Hematol"},{"issue":"18","key":"2025120616350009700_hem2025000753C26","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1182\/bloodadvances.2023010292","article-title":"Fertility counseling and sickle cell disease: clinical and ethical challenges for adolescent boys","volume":"7","author":"Nahata","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"2025120616350009700_hem2025000753C27","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/ajh.26495","article-title":"Pregnancy outcomes with hydroxyurea use in women with sickle cell disease","volume":"97","author":"Kroner","year":"2022","journal-title":"Am J Hematol"},{"key":"2025120616350009700_hem2025000753C28","unstructured":"Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation (HELPFUL). ClinicalTrials.gov. Identifier: NCT04093986. Posted 18September2019."},{"issue":"9","key":"2025120616350009700_hem2025000753C29","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1182\/blood.2023020728","article-title":"How I treat sickle cell disease in pregnancy","volume":"143","author":"James","year":"2024","journal-title":"Blood"},{"key":"2025120616350009700_hem2025000753C30","doi-asserted-by":"crossref","first-page":"14","DOI":"10.21037\/aob-24-14","article-title":"Advancing through challenges: current strategies in sickle cell disease management","volume":"9","author":"Alan","year":"2024","journal-title":"Ann Blood"},{"key":"2025120616350009700_hem2025000753C31","first-page":"465","article-title":"[P-selectin and its role in some diseases]","volume":"63","author":"Polek","year":"2009","journal-title":"Postepy Hig Med Dosw"},{"issue":"5","key":"2025120616350009700_hem2025000753C32","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2025120616350009700_hem2025000753C33","doi-asserted-by":"crossref","first-page":"e248","DOI":"10.1016\/S2352-3026(24)00384-3","article-title":"Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial","volume":"12","author":"Abboud","year":"2025","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2025120616350009700_hem2025000753C34","first-page":"146","article-title":"Primary analysis of Spartan: a phase 2 trial to assess the efficacy and safety of crizanlizumab in patients with sickle cell disease related priapism","volume":"142","author":"Anderson","year":"2023","journal-title":"Blood"},{"key":"2025120616350009700_hem2025000753C35","unstructured":"A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-Occlusive Crises. ClinicalTrials.gov. Identifier: NCT04935879. Posted 24June2021."},{"issue":"3","key":"2025120616350009700_hem2025000753C36","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of l-glutamine in sickle cell disease","volume":"379","author":"Niihara","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"2025120616350009700_hem2025000753C37","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1080\/14656566.2024.2377711","article-title":"Advances in pharmacotherapy for sickle cell disease: what is the current state of play?","volume":"25","author":"Alan","year":"2024","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"2025120616350009700_hem2025000753C38","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1182\/hematology.2023000486","article-title":"The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally","volume":"2023","author":"Kassim","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"26","key":"2025120616350009700_hem2025000753C39","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1182\/blood.2024024519","article-title":"How I treat sickle cell disease with gene therapy","volume":"144","author":"Sharma","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2025120616350009700_hem2025000753C40","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jpain.2023.09.014","article-title":"Buprenorphine, it works so differently\u201d: adults with sickle cell disease describe transitioning to buprenorphine for treatment of chronic pain","volume":"25","author":"Prince","year":"2024","journal-title":"J Pain"},{"issue":"suppl 1","key":"2025120616350009700_hem2025000753C41","article-title":"Empowering minds, easing pain: the role of talk therapy in sickle cell disease","volume":"1","author":"Alan","year":"2024","journal-title":"J Sickle Cell Disease"},{"issue":"1","key":"2025120616350009700_hem2025000753C42","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/j.pain.0000000000003009","article-title":"A cognitive-behavioral digital health intervention for sickle cell disease pain in adolescents: a randomized, controlled, multicenter trial","volume":"165","author":"Palermo","year":"2024","journal-title":"Pain"},{"issue":"24","key":"2025120616350009700_hem2025000753C43","doi-asserted-by":"crossref","first-page":"6257","DOI":"10.1182\/bloodadvances.2024013861","article-title":"Digital cognitive behavioral therapy vs education for pain in adults with sickle cell disease","volume":"8","author":"Jonassaint","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"2025120616350009700_hem2025000753C44","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.fertnstert.2018.05.016","article-title":"Risks associated with fertility preservation for women with sickle cell anemia","volume":"110","author":"Pecker","year":"2018","journal-title":"Fertil Steril"},{"issue":"3","key":"2025120616350009700_hem2025000753C45","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1124\/jpet.121.000743","article-title":"Etavopivat, a pyruvate kinase activator in red blood cells, for the treatment of sickle cell disease","volume":"380","author":"Schroeder","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"issue":"19","key":"2025120616350009700_hem2025000753C46","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1182\/blood.2022015403","article-title":"A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease","volume":"140","author":"Xu","year":"2022","journal-title":"Blood"},{"issue":"16","key":"2025120616350009700_hem2025000753C47","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1182\/bloodadvances.2023012467","article-title":"Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease","volume":"8","author":"Saraf","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"2025120616350009700_hem2025000753C48","doi-asserted-by":"crossref","first-page":"e70310","DOI":"10.1111\/hex.70310","article-title":"Barriers to care for adults with sickle cell disease: a qualitative descriptive study","volume":"28","author":"Grismore","year":"2025","journal-title":"Health Expect"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/585\/2470189\/585alan.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/585\/2470189\/585alan.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:35:08Z","timestamp":1765056908000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/585\/556907\/The-right-patient-the-right-treatment-tailoring"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000753","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}